Your browser doesn't support javascript.
loading
POTENTIAL TREATMENT FOR PERIPAPILLARY PACHYCHOROID SYNDROME.
Pothof, Alexander B; Fernández-Avellaneda, Pedro; Behar-Cohen, Francine; Martinez Ciriano, José P; Yzer, Suzanne.
Afiliación
  • Pothof AB; Department of Ophthalmology, Rotterdam Eye Hospital, Rotterdam, the Netherlands.
  • Fernández-Avellaneda P; Department of Ophthalmology, Basurto University Hospital, Bilbao, Spain; and.
  • Behar-Cohen F; Department of Ophthalmology, University Paris Descartes, Paris, France.
  • Martinez Ciriano JP; Department of Ophthalmology, Rotterdam Eye Hospital, Rotterdam, the Netherlands.
  • Yzer S; Department of Ophthalmology, Rotterdam Eye Hospital, Rotterdam, the Netherlands.
Retin Cases Brief Rep ; 17(4): 425-429, 2023 Jul 01.
Article en En | MEDLINE | ID: mdl-37364202
PURPOSE: The purpose of this study was to describe the effect of topical prednisolone on intraretinal fluid in patients with peripapillary pachychoroid syndrome. METHODS: We selected 11 consecutive patients (17 eyes) with a diagnosis of peripapillary pachychoroid syndrome, who were treated with topical prednisolone (Pred Forte [PF] 10 mg/mL) three times daily for 4 weeks. We tapered off PF among patients who demonstrated a reduction of intraretinal fluid. RESULTS: Of the included 17 eyes, the average follow-up before PF treatment ranged from 6 to 192 months, during which patients experienced no apparent reduction of intraretinal fluid. The baseline mean best-corrected VA (BCVA) was 0.6 (20/33) Snellen. The median subfoveal and peripapillary choroidal thickness were 430 µm and 202 µm, respectively. All patients showed an initial reduction of intraretinal fluid after 4 weeks of topical prednisolone. Six patients (35%) experienced a prolonged reduction of intraretinal fluid when the dosage was reduced to once daily. On tapering off PF, four eyes (24%) experienced a recurrence of intraretinal fluid. Four eyes (24%) experienced elevated intraocular pressure above 26 mmHg. In two eyes, PF was discontinued, on which intraretinal fluid reappeared. The BCVA seemed to be improved in 9 eyes (53%) and remained equal in 4 eyes (24%). CONCLUSION: In this case series of patients with peripapillary pachychoroid syndrome, we observed a reduction of peripapillary intraretinal fluid after treatment with topical prednisolone for 4 weeks in all 17 eyes. The disappearance of intraretinal fluid seemed to concede with a slight improvement in BCVA for some cases. Thus, topical prednisolone may prove to be a viable treatment option in peripapillary pachychoroid syndrome.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glaucoma Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Retin Cases Brief Rep Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glaucoma Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Retin Cases Brief Rep Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos